Grünenthal’s proprietary NaV 1.8 inhibitor enters clinical development18.2.2026 11:52:51 CET | news aktuell GmbH | Press release
Aachen, Germany, 18 February 2026 – Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in the second half of 2026.
















